Immunology and inflammation

News

Aclaris slashes staff as it trims its pipeline

Aclaris Therapeutics has said it will cut 46% of its workforce after deciding to discontinue the development of lead drug zunsemetinib (ATI-450) for immuno-inflammatory in

News

InDex craters on phase 3 ulcerative colitis failure

InDex Pharmaceuticals has said it will abandon a phase 3 trial of its lead drug cobitolimod in moderate-to-severe ulcerative colitis, its only clinical-stage programme, wr

News

Rumour confirmed as Roche buys Telavant for $7.1bn

Roche has announced a $7.1 billion deal to acquire Roivant group company Telavant and its RVT-301 drug candidate for inflammatory bowel disease (IBD), confirming rumours t

News

AbbVie’s Skyrizi bests Stelara in Crohn’s contest

AbbVie has built the case for its IL-23 inhibitor Skyrizi as a treatment for Crohn’s disease, saying its drug was more effective than Johnson & Johnson’s widely-used S

News

MSD gives warning to UK ahead of $1.3bn facility work

In 2017, MSD made the decision to open a $1.32 billion, 220,000 sq ft research facility in the heart of London’s ‘knowledge quarter’ around King’s Cross.

News

Lilly to file mirikizumab in Crohn’s after FDA colitis snub

Eli Lilly has said it plans to file its anti-IL-23p19 antibody mirikizumab for approval as a treatment for Crohn’s disease next year after it hit all its targets in a phas

Aclaris slashes staff as it trims its pipeline

InDex craters on phase 3 ulcerative colitis failure

Rumour confirmed as Roche buys Telavant for $7.1bn

AbbVie’s Skyrizi bests Stelara in Crohn’s contest

MSD gives warning to UK ahead of $1.3bn facility work

Lilly to file mirikizumab in Crohn’s after FDA colitis snub

BioNTech sticks with cancer vaccine despite trial miss

Discover a new era of healthcare panel engagement: Grounded ...

Immunology and inflammation

Editor's Picks